All In Biotech

Drug Trial Radar · NCT06871761

A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 Injection With Insulin Glargine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin, Metformin in Combination With or Without One Other Oral Antidiabetic Drug (OAD)

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 393 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

393

Actual

Start

May 8, 2024

Primary completion

May 13, 2025

Study completion May 13, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and hypoglycemic events.

Conditions

  • Adult Patients With Type 2 Diabetes

Interventions

  • HR17031 injectionDrug

    HR17031 injection

  • insulin glargineDrug

    insulin glargine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in HbA1c from baseline to week 26Time frame: from baseline to week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Zhu Xianyi Memorial Hospital, Tianjin Medical University

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.